1. Anticoagulants in Interventional Cardiology:

2. Overview of Anticoagulation in Interventional Cardiology

3. Rivaroxaban in Patients With Recent ACS: ATLAS ACS 2-TIMI 51

4. Apixaban After ACS: APPRAISE-2

5. How Do You Treat Complex Patients?

6. ACC/AHA Guidelines

7. ESC Guidelines

8. The Use of NOACs in the Setting of AF and PCI

9. AF Patients Undergoing PCI

10. Triple vs Dual Combination Therapy Post-PCI: WOEST Trial

11. New Era With NOACs: PIONEER AF-PCI Study Design

12. PIONEER AF-PCI: Clinically Significant Bleeding

13. PIONEER AF-PCI: MACE

14. RE-DUAL PCI: Trial Design

15. RE-DUAL PCI: ISTH Major or CRNM Bleeding

16. RE-DUAL PCI: Thromboembolic Events, Death, or Unplanned Revascularization

17. RE-DUAL PCI: Definite Stent Thrombosis

18. AUGUSTUS: Study Design

19. ENTRUST-AF PCI: Study Design

20. Antithrombotic Strategy Considerations

21. Antithrombotic Strategies for Complex Patients With AF Following PCI

22. Exploring the Use of NOACs in the Setting of TAVR

23. Transcatheter Aortic Valve Replacement/Implantation

24. Post-TAVR DAPT

25. Many Unknowns With TAVR

26. TAVR Trials

27. Current Guideline Recommendations for TAVR

28. ATLANTIS Trial: Apixaban vs Standard of Care

29. GALILEO Trial Design: Rivaroxaban vs Clopidogrel

30. ENVISAGE-TAVI: Edoxaban- vs VKA-Based Regimen

31. Interim Treatment Suggestions Until More Data Become Available for TAVR Patients

32. Transitioning Care From Post-Procedure to Long-Term Management

33. Follow-Up Considerations

34. Different Durations of Therapy Patient Scenarios

35. Patient Anticoagulation Education

36. NOAC Antidotes

37. Conclusion

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)